The cost-effectiveness of treating triple coinfection with HIV, tuberculosis and hepatitis C virus.
The objective of this study was to estimate the cost-effectiveness of treating patients infected with HIV and simultaneously coinfected with tuberculosis (TB) and hepatitis C virus (HCV).



A mathematical model for HIV coinfection with TB and HCV is introduced. The model was designed to incorporate parameters of control for the coverage of care, which makes it useful for performing cost-effectiveness analysis of public policies. A cost-effectiveness analysis of early medical care of patients with TB and HCV coinfection, with coverage of 0 (basal), 25, 50, 75 and 100%, was performed for the whole cohort of patients and a special analysis was performed in a selected population with triple infection.



The cost per resolved infection and the cost per year of life gained were found to be very cost-effective for the population with triple infection, for all different coverages.



It is known that treating patients with HIV who are coinfected with TB or HCV implies high cost and low efficacy, but it is possible that the population with triple infections could achieve important benefits in terms of years of life gained.
Immunology Division, National Institute of Public Health, Cuernavaca, Mexico.
G
G
Sánchez-González
D000995:Antitubercular Agents / Q000008:administration & dosage / Q000191:economics*; D000998:Antiviral Agents / Q000008:administration & dosage / Q000191:economics*; D015331:Cohort Studies; D060085:Coinfection / Q000188:drug therapy*; D003362:Cost-Benefit Analysis; D015658:HIV Infections / Q000150:complications / Q000188:drug therapy*; D019698:Hepatitis C, Chronic / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D008962:Models, Theoretical; D014376:Tuberculosis / Q000150:complications / Q000188:drug therapy*
D000995:Antitubercular Agents; D000998:Antiviral Agents
HIV; Hepatitis C Virus; Tuberculosis